Malignant melanoma stage II – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:04 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Malignant melanoma stage II – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety of Continued Treatment with GME751 (Pembrolizumab Biosimilar) for Patients with Melanoma or Non-Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-on-the-safety-of-continued-treatment-with-gme751-pembrolizumab-biosimilar-for-patients-with-melanoma-or-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:59:27 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-continued-treatment-with-gme751-pembrolizumab-biosimilar-for-patients-with-melanoma-or-non-small-cell-lung-cancer/ This clinical trial is focused on studying the effects of continued treatment with a medication called GME751, which is a proposed biosimilar to pembrolizumab. The study is designed for participants who have previously been treated with pembrolizumab in earlier studies and are eligible to continue this treatment. The diseases being studied in this trial are melanoma, a type of skin cancer, and non-small-cell lung cancer (NSCLC), which is a common type of lung cancer.

The purpose of the study is to assess the safety of ongoing treatment with GME751 by monitoring the occurrence of serious adverse events (SAEs). Participants will receive the treatment through an intravenous infusion, which means the medication is delivered directly into a vein. The study will follow participants for a period of up to 24 months to observe any potential side effects or reactions to the treatment.

In addition to GME751, some participants may have previously received another medication called Pemetrexed, which is used in combination with other treatments for certain types of cancer. The study is open-label, meaning both the researchers and participants know which treatment is being administered. This trial aims to provide valuable information on the safety of continuing treatment with GME751 for individuals with melanoma and NSCLC.

]]>